Product Description
BIIB021 is a novel, fully synthetic inhibitor of Hsp90 that binds competitively with geldanamycin in the ATP-binding pocket of Hsp90. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19372565/)
Mechanisms of Action: HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Gastrointestinal Stromal Tumors
Phase 1: Breast Cancer|Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2009-014796-51 | P2 |
Completed |
Breast Cancer |
2011-10-31 |
|
120BC201 | P2 |
Completed |
Breast Cancer |
2011-10-01 |
|
120BC101 | P1 |
Completed |
Breast Cancer |
2011-04-01 |
|
120ST104 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2010-08-01 |